💰 InSilico Medicine and Aska Pharmaceutical expand women’s health drug discovery partnership
InSilico Medicine and Aska Pharmaceutical have expanded their collaboration to accelerate discovery of novel drug targets in women’s health, combining AI-driven drug discovery with clinical expertise to advance new therapies across key conditions.
"I am honored to lead this collaboration with ASKA. With our latest disease-specific TargetPro models, we look forward to helping ASKA develop the next generation of treatments for women worldwide." — Dr. Frank Pun, Head of Insilico Medicine's Hong Kong site
🧬 Persevere Therapeutics raises seed funding to advance cancer therapeutics pipeline
Persevere Therapeutics has secured seed funding to advance its pipeline of cancer therapies, with a focus on precision medicine approaches and translational research to bring new treatments into clinical development.
“We saw great safety, great tolerability … we had some really interesting signals of efficacy, which [were] encouraging us enough to form the company, Persevere, and launch it. We want to make sure we raise either enough capital to advance it into multiple cancers, or partner this with a company that can advance into multiple cancers.” — Greg Bosch, Founder & CEO, Persevere Therapeutics
🌵 Prickly Pear Health expands pre-seed funding to over $600K to scale women’s health platform
Arizona-based Prickly Pear Health has expanded its pre-seed round to more than $600,000, backed by Emmeline Ventures, to grow its platform supporting women navigating chronic conditions such as endometriosis and PCOS.
"I founded Prickly Pear Health to address a critical blind spot in women's healthcare: how hormonal changes impact brain health. This round reflects a powerful coalition of partners who believe that women deserve better tools to understand what's happening in their brains during life transitions." — Imen Maaroufi Clark, Founder & CEO, Prickly Pear Health
🧪 FDA clears LiviWell post-intercourse device to support vaginal health
The FDA has cleared LiviWell’s post-intercourse fluid absorption device, designed to support vaginal health and reduce the risk of infections, offering a new non-pharmaceutical solution in intimate care.
"Conversations around post-sex vaginal health have historically been limited. Achieving FDA clearance for Livi represents an important step toward bringing greater medical recognition and innovative solutions to women experiencing these everyday concerns." — Michael Ingber, Chief Medical Officer, LiviWell
🏛️ California plans $3.4M menopause care overhaul to expand access and awareness
California is proposing $3.4 million in funding to improve menopause care, including expanded screening from age 40, better insurance coverage for treatments and increased education for clinicians and patients.
🔗 https://www.femtechworld.co.uk/menopause/california-plans-us3-4m-menopause-care-overhaul/
💼 Nordea holds $37.8M stake in Prestige Consumer Healthcare
Nordea Investment Management has disclosed holdings of approximately $37.8 million in Prestige Consumer Healthcare, a company with a portfolio that includes women’s health products across OTC and wellness categories.
